Iohexol vs. metrizamide: study of efficacy and morbidity in cervical myelography

AJNR Am J Neuroradiol. 1985 Nov-Dec;6(6):931-3.


A double-blind study was conducted in 60 patients undergoing either cervical or more complete myelography via C1-C2 puncture. Patients received either iohexol or metrizamide at a 300 mg l/ml concentration. The contrast media were equally efficacious in the production of high-quality radiographs and CT scans. However, the incidence of adverse reactions differed markedly. Of patients receiving metrizamide, 68% had some type of adverse reaction, whereas only 26% receiving iohexol had symptoms. The incidence of headache (metrizamide, 34%; iohexol, 26%) was not statistically different, but the quality of the headache differed: half of the metrizamide headaches were moderate or severe, whereas all iohexol headaches were mild. Nausea (31%) and vomiting (28%) were common with metrizamide but unusual (3% nausea) with iohexol. Of the metrizamide patients, 21% had overt psychologic changes that did not occur in the iohexol group.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Cervical Vertebrae
  • Clinical Trials as Topic
  • Contrast Media* / adverse effects
  • Female
  • Headache / chemically induced
  • Humans
  • Iodobenzoates*
  • Iohexol
  • Male
  • Metrizamide* / adverse effects
  • Middle Aged
  • Myelography / methods*
  • Nausea / chemically induced
  • Triiodobenzoic Acids* / adverse effects
  • Vomiting / chemically induced


  • Contrast Media
  • Iodobenzoates
  • Triiodobenzoic Acids
  • Iohexol
  • Metrizamide